key: cord-0741676-slhqi9so
authors: Bown, Chad P.; Bollyky, Thomas J.
title: How COVID‐19 vaccine supply chains emerged in the midst of a pandemic
date: 2021-08-19
journal: World Econ
DOI: 10.1111/twec.13183
sha: de1009f8cde08842a11bb92d7a09a375f8abbf0a
doc_id: 741676
cord_uid: slhqi9so

Many months after COVID‐19 vaccines were first authorized for public use, still limited supplies could only partially reduce the devastating loss of life and economic costs caused by the pandemic. Could additional vaccine doses have been manufactured more quickly some other way? Would alternative policy choices have made a difference? This paper provides a simple analytical framework through which to view the contours of the vaccine value chain. It then creates a new database that maps the COVID‐19 vaccines of Pfizer/BioNTech, Moderna, AstraZeneca/Oxford, Johnson & Johnson, Novavax and CureVac to the product‐ and location‐specific manufacturing supply chains that emerged in 2020 and 2021. It describes the choppy process through which dozens of other companies at nearly 100 geographically distributed facilities came together to scale up global manufacturing. The paper catalogues major pandemic policy initiatives—such as the United States’ Operation Warp Speed—that are likely to have affected the timing and formation of those vaccine supply chains. Given the data, a final section identifies further questions for researchers and policymakers.

other vaccine candidates-especially from India (Bharat Biotech) and Russia (Sputnik V)-had already been put into circulation domestically and in selected countries even before they received WHO emergency use listing. With the exception of Johnson & Johnson, each of these vaccines involved a two dose regimen. Other attempts-including by major industry players such as Merck and Sanofi/GSK, as well as CureVac-did not clear clinical trials. That so many candidates made it through so quickly is a scientific anomaly.

The geographic concentration of vaccine production was one reason why trade would play a substantial role in inoculating much of the global population. Most of Sub-Saharan Africa, for example, as well as low-and middle-income countries elsewhere, rely on imports, as they had little pre-pandemic experience manufacturing vaccines locally. Trade was also critical because of the cross-border nature of many vaccine supply chains that emerged during the pandemic, including trade in specialized inputs, the manufacturing of which was also characterized by the geographic concentration of suppliers.

Production of most of the COVID-19 vaccines involved the establishment of multiple supply chains, partly out of fears that governments would resort to "vaccine nationalism"-i.e., refusal to export doses, at least until their populations had been fully served. 10 The possibility of this outcome was made obvious to pharmaceutical companies early in the pandemic, when the Trump administration demanded contractual terms that vaccines manufactured in the United States remain there, as the property of the US government.

The United States was not alone: The UK government publicly adopted a similar strategy. 11 Companies thus quickly learned that providing vaccines to other markets meant also manufacturing them from other markets.

Some of these vaccines also required additional nodes of production-separate mini-supply chains-feeding into the main manufacturing supply chain illustrated in figure 1. Pfizer/BioNTech and Moderna, for example, required massive volumes of lipid nanoparticles, and Novavax required a specialized adjuvant, a product that helps boost the body's immune response to the antigen.

Finally, companies would complain about limited availability of critical inputs throughout the pandemic. At times there were too few single-use bioreactor bags, filtration pumps, filters, skilled workers, financial capital, and even partner companies with idle capacity to quickly scale up their production processes.

BioNTech-a biotech firm located in Mainz, Germany founded by Özlem Türeci, a child of Turkish immigrants, and Uğur Şahin, a Turkish immigrant-invented a messenger ribonucleic acid (mRNA) COVID-19 vaccine early in 2020. On March 17, it announced a partnership with Pfizer in which the global pharmaceutical company would assist in clinical development and manufacturing for all markets outside of China. The two companies had a prior commercial relationship; in August 2018, for example, they had signed a collaborative agreement to develop mRNA-based vaccines for the prevention of influenza. The Pfizer/BioNTech candidate would be the first vaccine to receive authorization for emergency use by four of the main regulators, getting the nod from the MHRA, the FDA, the EMA, and the WHO in December 2020 (see table 3 ).

Pfizer and BioNTech had begun setting up their vaccine supply chains much earlier. Production would initially take place through a web of existing plants, most of them belonging to Pfizer (figure 2). 12 To start, Pfizer developed the first stage of the drug product (DNA plasmids) at a plant in Missouri. These plasmids were then frozen, packed, and shipped to two plants-a Pfizer facility in Andover, Massachusetts, and a BioNTech site in Mainz. At those plants, the DNA was turned into the mRNA-the active pharmaceutical ingredient. Bags of filtered mRNA were then sent to two additional sites for the last stage of formulation, fill and finish. The Andover mRNA was sent to a Pfizer plant in Michigan, and the Mainz mRNA was sent to a Pfizer facility in Puurs, Belgium. From there, the vaccine vials were packaged and distributed.

The formulation prepared at the facilities in Michigan and Belgium required vast supplies of lipid nanoparticles to combine with the mRNA. The lipids had their own specialized supply chains. BioNTech licensed technology from Acuitas, a Canadian firm, but the lipids were then manufactured at scale elsewhere.

Pfizer's lipids were produced by Avanti Polar Lipids of Alabama, a subsidiary of the British company, Croda, under a five-year contract signed in November. Croda also had a plant in Snaith in the United Kingdom; the Telegraph reported that it was the source for the essential lipid nanoparticles used by Pfizer in the Belgian plant. 13 This finding is consistent with the data illustrating a sharp increase in UK exports of lipids, first to Belgium and then to Germany in early 2021 (figure 3). The Financial Times later reported that this flow of 12 See Emma Cott, Elliot deBruyn, and Jonathan Corum, "How Pfizer Makes Its Covid-19 Vaccine," New York Times, April 28, 2021; Elizabeth Weise and Karen Weintraub, "A COVID-19 Vaccine Life Cycle: From DNA to Doses," USA Today, February 7, 2021. 13 A spokesperson for Croda International said, "We manufacture components within the UK that we ship to Pfizer facilities in multiple locations, including Belgium." See Bill Gardner and Ben Riley-Smith, "Exclusive: Pfizer Warns EU to Back Down on Covid Vaccine Threat to UK," Telegraph, March 19, 2021. Accepted Article exports from Britain was the input dependence that kept the European Commission from imposing export restrictions on AstraZeneca vaccines in early 2021, involving a dispute described below. 14 BioNTech subsequently contracted with firms like Evonik and Merck KGaA to manufacture lipids at facilities within the European Union, not just the United Kingdom, perhaps out of growing concern that UK-EU tensions over the AstraZeneca vaccine would put their supply chains at risk.

Given the early successes of the Pfizer/BioNTech vaccine, demand increased. The companies expanded each element of their US and European supply chains to increase capacity (see the bottom panel of figure 2 ). Pfizer announced that it would manufacture lipid nanoparticles at one of its plants in Connecticut, and it added new vaccine formulation capacity in Michigan, as well as more fill and finish at another facility in Kansas. (It also signed up Exelead, a CDMO with experience producing lipid nanoparticles, to help scale up production.) For Europe, Pfizer began to use one of its plants in Ireland, and BioNTech's newly acquired plant from Novartis in Marburg, Germany became operational in February 2021. BioNTech signed up other firms to formulate the mRNA active ingredients or produce lipids, as well as Siegfried, Delpharm, Sanofi, Novartis, and Thermo Fisher to fill and finish in various plants across Europe, taking some of the load off the Pfizer facility in Belgium (which nevertheless also expanded capacity).

It would take much longer for the Pfizer/BioNTech vaccine to build capacity outside of the United States and Europe. Only in May 2021, for example, did BioNTech announce construction of a new manufacturing facility in Singapore, to be subsidized by the Singaporean government; the plant is not expected to become operational until 2023. Although BioNTech had disclosed a partnership with Shanghai Fosun Pharmaceutical to distribute its vaccine in China in March 2020, it took until May 2021 before they formally agreed for the joint venture to produce at a manufacturing facility owned by Fosun in China. And only in July 2021 did Pfizer and BioNTech strike a deal with the Biovac Institute in South Africa to use its Cape Town facility to fill and finish the vaccine supplied from plants in Europe for distribution across the African Union beginning in 2022.

Despite their extraordinary success, Pfizer and BioNTech ran into input shortages as they attempted to expand. As Uğur Şahin explained in an interview with Der Spiegel in January 2021, 15 "We are currently trying to find new cooperation partners who will be able to produce the vaccine for us. But it's not as if there are unused, specialized factories sitting around the world that can start producing the vaccine tomorrow in the quality necessary."

The companies also worried about running short of specific inputs for their existing production facilities.

Unlike the other vaccine companies with which the US government contracted in 2020, Pfizer's first contract in July was not given a "priority rating" under the Defense Production Act (DPA). Without the priority rating, Pfizer was not able to jump to the head of the line on supply acquisition, as discussed later in this paper.

Pfizer reportedly struggled and requested US government help "to give the company better access to roughly nine specialized products it needs to make the vaccine," including lipids. 16 The Wall Street Journal later reported that initial shortages meant that "Pfizer figured out how to stretch scarce supplies of special filters needed for the vaccine production process by recycling them." 17 When asked in mid-December 2020 whether Pfizer would request the US government to invoke the DPA on its behalf, CEO Albert Bourla said, 18 "We are asking them, and I hope that they will do it very soon because, particularly in some components, we are running at critical supply limitations." Pfizer's second contract with the US government, signed December 22, was granted a DPA priority rating. Then, on February 5, 2021, shortly after assuming office, the Biden administration announced that it was further "expanding the priority ratings for Pfizer to include filling pumps and tangential flow filtration skid units, critical components Pfizer needs to manufacture the COVID vaccine." 19

Moderna is a Cambridge, Massachusetts biotech start-up founded in 2010. In collaboration with scientists at NIH, Moderna also invented an mRNA vaccine candidate. To support its Phase 2 and 3 trials, it first teamed with PPD, a contract research organization. Moderna reportedly ran into hiccups with regulators along the way 20 -one potential example of learning by doing for a company without much experience in vaccine trials- 16 

This article is protected by copyright. All rights reserved which may have slightly delayed its deployment. Nevertheless, Moderna received emergency use authorization from the FDA on December 18, 2020. 21 Moderna took a very different approach from Pfizer and BioNTech to create its manufacturing supply chain (figure 4). Unlike those companies, it had to start from scratch. Moderna had a facility in Massachusetts for manufacturing smaller batches of its vaccine for clinical trials, but that plant was not large enough for commercial-scale production. It teamed with Lonza, a global CDMO, signing a 10-year strategic contract May 1, 2020. Lonza established production lines at a plant in New Hampshire, partly supported by US government funding, as well as at another facility in Switzerland for vaccine sales destined for outside the US market. (The Swiss facility did not appear to be subsidized at risk and was thus slower to come online. 22 23 There is evidence of a substantial increase in exports of vaccines from Switzerland to first Spain and then France in 2021, consistent with Moderna's drug product being exported to those two countries for fill and finish (figure 5).

Moderna also publicly complained about input shortages hampering its ability to increase production, especially when shipments to the United Kingdom and Canada from its European supply chain were lower than expected in early 2021. CEO Stéphane Bancel stated unequivocally, "The bottleneck right now is people," complaining that Modern's partner Lonza could not find enough local skilled workers to expand its 21 In Japan, Moderna would also contract with Takeda to run its clinical trials. 22 Reuters reported that three new production lines in Visp, Switzerland "costing 70 million Swiss francs ($80 million) each and due to supply a combined 300 million doses annually, are not yet producing vaccine, though the first line could become operational within days. A Lonza site in Portsmouth, New Hampshire, with 100 million doses annual capacity, began large-scale production last year for US-bound Moderna vaccine" (John Miller, "Moderna Vaccine to Criss-Cross Continent before Europeans Get Shots," Reuters, January 6, 2021). 23 Moderna also announced that Samsung Biologics would do fill and finish in South Korea, but it did not initially indicate where the drug product would be imported from.

This article is protected by copyright. All rights reserved European facilities. It asked the Swiss government to streamline work visas and sought to borrow specialist staff from other Swiss companies. 24

AstraZeneca was at the heart of four controversies-each a case study of problems that can emerge when attempting to quickly scale up vaccine manufacturing. Despite this UK-centric supply chain-partially facilitated by the UK government, as described below-AstraZeneca's vaccine aspirations were global. But AstraZeneca would end up mostly coordinating multiple CDMOs into a global supply chain network rather than tapping its own facilities and operating as a globally integrated pharmaceutical company (figure 6). That decision may have partially contributed to many of the challenges that emerged.

The clinical trial, data, and public health controversies 

This article is protected by copyright. All rights reserved Bollyky and Bown (2021) .

This article is protected by copyright. All rights reserved in the United States had actually increased considerably in the six months from October 2020 to March 2021 (figure 7).

Poonawalla seemed to reverse course again in a stunning interview with the Financial Times on May 2.

Instead of input shortages holding back production, he claimed, he had decided against expanding SII's production capacity earlier because "there were no orders, we did not think we needed to make more than 1 billion doses a year." 32 India was suffering perhaps the worst disease outbreak of anywhere in the world at that point, and Poonawalla temporarily escaped to London.

A second troublesome supply chain for AstraZeneca involved its US-based production. Plans started quickly, however, and initially with high expectations. In June 2020, AstraZeneca signed an agreement with Emergent

BioSolutions to produce its drug substance in Maryland, with funding from the US government, initially to produce investigational doses for use in its clinical trials. (In July 2020, an agreement was made for the Emergent facility to expand capacity from clinical to commercial scale.) In August, Catalent announced that it would also produce AstraZeneca's drug substance at a nearby Maryland facility. Fill and finish for the USmanufactured product would be done at an AstraZeneca plant-potentially the only AstraZeneca facility put to early use for COVID-19 vaccine production in its global supply chain-in Ohio. In late October, AstraZeneca 

Although AstraZeneca suffered growing pains with its US, Indian, and European supply chains, as well as public health scares, its vaccine continued to play a global role in flighting the pandemic. The company contracted with numerous other partners to build out its supply chain elsewhere (see figure 6 ).

In June 2020, Brazil's state-run Fiocruz Institute announced that it would do fill and finish for AstraZenecafor drug substance initially produced at SII-and eventually also manufacture the drug substance itself. Kangtai indicated that it expected to be able to produce 400 million doses of the vaccine a year.

In Australia, CSL announced in August 2020 that it would produce drug substance at a plant in Broadmeadows, performing fill and finish locally at a plant in Parkville. In December, Japan's JCR Pharmaceuticals Company agreed to make the vaccine at a newly built plant in Kobe, with Daiichi Sankyo handling fill and finish. KM Biologics reportedly also signed up to do fill and finish. In Europe, the supply chain was set up to receive drug substance from the Leiden plant. For fill and finish, 

These COVID-19 vaccines, and the timing, geography, and firm-to-firm relationships in their manufacturing supply chains, did not emerge randomly. Neither did policy, which likely played an important role. 

This article is protected by copyright. All rights reserved 2021-and thus how alternative policy choices might have allowed things to evolve differently-will be a challenge. This section catalogues key government initiatives that are likely to have been important.

The US government announced the framework behind Operation Warp Speed (OWS) on May 15, 2020. 57 It used the Department of Defense, the Department Health and Human Services, the Biomedical Advanced

Research and Development Authority (BARDA), and other agencies to create OWS to coordinate clinical trials and scale up manufacturing in advance of regulatory approval of potential vaccines. This "at-risk" approachspending money that would be lost if a vaccine were not ultimately approved-was essential to making rapid progress. OWS also helped expedite the development of viable vaccines able to obtain authorization from the FDA for emergency public use. 

This article is protected by copyright. All rights reserved OWS also coordinated and matched contract manufacturers with vaccine sponsors to ensure that those purchase orders would be fulfilled. It made at-risk investments with Emergent BioSolutions, GRAM, and FDB in May-November 2020, as well as matching them to AstraZeneca, Johnson & Johnson, and Novavax. The funding and partnerships allowed those facilities to begin earlier than others the process of acquiring the specialized equipment, inputs, and technology necessary and prepare for drug substance manufacturing, formulation, and fill and finish.

Despite funding and lead-time, much of the manufacturing scale-up in the United States did not go smoothly.

Recall Technologies; and Smiths Medical in an attempt to head off concern that once the vaccines had been manufactured, holdups might arise because of shortages of complementary inputs needed for delivery.

The DPA was the second potentially important US policy initiative deployed to expand vaccine manufacturing during the pandemic. 59 The US government gave priority ratings under DPA to each vaccine maker's contract in 2020. (The exception was Pfizer, which did not receive a priority rating for its initial contract in July but did for its second contract for an additional 100 million doses on December 22.) A priority-rated contract had two primary effects. First, vaccine manufacturers had to use their US facilities to prioritize US government orders 59 See Bown and Rogers (2021) and Bollyky and Bown (2021) .

This article is protected by copyright. All rights reserved for doses over any other competing claims on their resources-forcing, for example, Moderna's US supply chain to satisfy a US government contract for 100 million doses before it could produce any other products or sell doses of its vaccines to other potential consumers, whether in the United States or abroad. Second, a priority-rated contract allowed vaccine makers to go to their input suppliers and demand that their contract be prioritized over any other orders for those same materials.

Prioritizing vaccine manufacturing likely untangled some potential input bottlenecks in the US supply chain.

For example, a DPA contract forced Catalent to tell Horizon to find another facility it had reserved to fill and finish Tepezza, its thyroid eye disease drug, because the Indiana plant had been ordered to bottle COVID-19

vaccines. 60 Furthermore, the US government also reportedly embedded military logistics experts into the supply chains to help facilitate the allocation of those scarce supplies. 61 This may have been a response to the highly likely event that the various vaccine manufacturers, each armed with priority-rated contracts, all placed nearly simultaneous orders for the same equipment and raw materials with the limited number of specialized input suppliers.

While there were numerous complaints, exactly what input shortages arose and whose orders got deprioritized because of DPA invocation remains unknown. The policy became a lightning rod when the Biden administration began to publicize its use for unlocking bottlenecks for Pfizer in early February 2021. 62 One direct problem with the DPA emerged from its lack of transparency.

Trading partners and vaccine manufacturers outside the United States reacted by accusing the US government of using DPA as an export-restricting policy, not simply to reallocate inputs toward higherpriority vaccine production and away from other uses. 

This article is protected by copyright. All rights reserved echoing similar sentiments in May. 64 Given the lack of transparency involving how and when DPA was used, it was impossible to refute accusations that the effect of the policy was to restrict exports. 

The UK government also made at-risk public investments in its domestic vaccine manufacturing supply chain during the pandemic, albeit to a lesser extent than the United States and in a somewhat different manner ( 

This article is protected by copyright. All rights reserved (AstraZeneca) and another from Imperial College London. The government also gave subsidies of £31 million to manufacture the vaccine candidates for clinical trials and £42 million to reserve fill-and-finish capacity for 18 months at UK sites. Over the following few months, it negotiated five binding advance purchase commitments, at a cost of £2.9 billion (for 267 million doses). Of that, the United Kingdom paid out £914 million up front, much of it nonrefundable, for the companies to further develop their clinical trials and set up their supply chains at risk. Concerned that allowing the last step to take place outside of its borders could put its access to vaccine doses at risk of potential EU export control policy, in March 2021 the UK government reportedly played matchmaker between Novavax and GSK to convince the latter to use an English facility for fill and finish. The GSK announcement described an agreement between GSK, Novavax, and the UK Government Vaccine Taskforce; no terms of government subsidies were mentioned. 69

The second component of the UK subsidy strategy involved more than £266 million designed to enhance the long-term ability of the United Kingdom to manufacture vaccines. It included training programs for staff and development of new national databases to speed up registrations needed for future clinical trials.

Other economies also subsidized vaccine manufacturers, but very differently, and mostly at much later points in the vaccine development process ( Other major economies, including Australia and Japan, also provided subsidies, but they appeared smaller in scope, arose much later, and did little to scale up the broader vaccine supply chain (see table 6 ). India only subsidized major vaccine manufacturers like SII and Bharat Biotech late in the process, beginning in April 2021. 

This article is protected by copyright. All rights reserved 

Researchers and policymakers will work for years distilling the details of COVID-19 vaccine manufacturing in order to address whether more doses could have been produced faster some other way. This section raises six economic questions for further investigation.

The fact that major economies heavily subsidized many more vaccine candidates than were ultimately deployed was unequivocally correct given the context of the pandemic, which killed millions and caused trillions of dollars in economic losses. A diverse portfolio was critical, because unpredictable real-world problems could (and did) emerge to affect any given candidate. Some subsidized candidates (e.g., Merck and IAVI) failed entirely. Others (e.g., Novavax, CureVac, Valneva, and Sanofi/GSK) may yet succeed clinically, but they will have taken much longer than Pfizer/BioNTech, Moderna, AstraZeneca, and Johnson & Johnson to obtain regulatory approval.

Even if appropriate in theory, some of the at-risk public investments to scale up manufacturing for candidates that regulators green-lighted (e.g., Emergent in the United States to produce AstraZeneca and Johnson & Johnson) proved problematic. Some facilities ran into quality control issues; others were slow to expand because of learning challenges or inadequate access to inputs. Government policies prevented some companies from exporting. The diversity of candidates and the global diversity of production mattered.

Pfizer and Moderna may turn out to be the success stories ex post. But if those previously untried technologies had not worked, vaccines from Johnson & Johnson, AstraZeneca, and even Novavax or CureVac might have played an even more important role than they did in saving lives. Some of these less successful vaccines may be relegated to the annals of history, but they were equivalent to an insurance policy. Evenett et al. (2021) note that the lack of at-risk subsidies during the previous, H1N1 pandemic of 2009-2010-and the fact that some companies were burned by making investments that could not be recouped, as governments pulled funding when that pandemic waned-may have played a role in the unwillingness of certain companies to act this time around. One lesson is that companies should not be punished for taking financial risks on society's behalf, lest those risks be discouraged the next time.

During the pandemic, vaccine manufacturers complained about a series of input shortages. Lipids, bioreactor bags, filtration pumps, filters, and other equipment and raw materials were in short supply, potentially slowing the scaling up of vaccine production. Some shortages were to be expected, given the surge in demand for customized inputs. But questions remain. Could alternative policies have discouraged input demand from becoming too concentrated in the same suppliers? Was there enough public investment in expanding the capacity of the companies manufacturing those key inputs? 72

Pall is a key vaccine equipment supplier and part of the consortium the Oxford vaccine originators convened in early April 2020. Clive Glover, Pall's director for cell and gene therapy, described the equipment implications: "The need to standardize was a necessity for this project because there are more than 20 different sites manufacturing [the Oxford (AstraZeneca) vaccine], each using the 50 or so consumables required for the manufacturing process. If each site had its own customized version, there would need to be more than 1,000 parts!" 73

Standardizing the equipment and production process for a vaccine across facilities would have costs and benefits. A benefit is the speed at which each new plant could scale up manufacturing of a consistent drug product, if they could access the standardized inputs. The cost is that, due to the specialized nature of some of those inputs, the standardized equipment may have been coming from a limited number of suppliers who found themselves unable to keep up with demand.

Policy-makers needed transparency regarding the capacity and utilization rates of the input providers in the vaccine supply chain to determine whether some were overburdened and needed, where feasible, to have their tasks reallocated to others. Use of DPA granted the US government some insight into the equipment and raw material providers that US vaccine manufacturers were using. Other governments did not have this insight, and the US government lacked information on the input demands of vaccine manufacturers in other countries, except when they complained about it publicly.

Another policy problem may have been too little global public investment in expanding the production capacity of those input suppliers. Although the United States, and to a lesser extent CEPI, subsidized upstream equipment and raw material providers in addition to downstream vaccine manufacturers, their efforts were likely insufficient.

One potential explanation involves the geographic concentration of the input suppliers. Suppose input providers were located primarily in the United States. Although US government subsidies may have been sufficient for the needs of domestic manufacturers and thus nationally optimal, they may have been globally suboptimal. The size of the globally optimal subsidies to US input providers may have been much larger, requiring expansion of input production capacity big enough to satisfy increases in demand also arising from vaccine manufacturers in Europe, India, and elsewhere.

A second, contributing explanation may have been that input suppliers were simply located in different countries from vaccine manufacturers. In theory, given the global nature of the pandemic, governments should have incentive to subsidize input providers even if the downstream manufacturers were located elsewhere. Such subsidies would address the positive externality of public health gains of resolving the pandemic affecting its population, since that population would have access to the final vaccines manufactured elsewhere through international trade. But as Bown and Bollyky (2021) explain, here the policy failure of too little input subsidies could arise due to concerns over vaccine export restrictions. Access to finished vaccines was highly uncertain during the pandemic, given the implicit and explicit export restrictions that vaccine manufacturing countries and groups of countries-including the United States, the United Kingdom, the European Union, and India-all employed.

The policy "failures" in these cases would be the lack of international policy coordination. 74 One contributing solution would be to create a mechanism for other countries to subsidize the expansion of US (or foreign) input capacity destined for their downstream manufacturers. Cooperation may also require an explicit, publicized, enforceable agreement between the major producers not to implement export-restricting policies and to establish some mutually acceptable way of transparently rationing inputs in short supply.

Once there were multiple viable candidates, legitimate questions arose about how to allocate and reallocate available inputs to best scale up overall production quickly. There is still much to be learned about the details of what happened. Could the process have been coordinated more efficiently across countries? Could public health and scientific evidence have played a more central role in determining which vaccines to produce where and when? What were the costs and unintended consequences of the allocation decisions that were made?

US use of the DPA reallocated orders of some raw materials and equipment toward vaccine manufacturers. It is likely that DPA was a useful way to reallocate some inputs and that, without well-functioning secondary markets, these input reallocations may not have happened. What is not known is what orders ended up being de-prioritized in favor of the vaccines.

There is anecdotal evidence that entire facilities were repurposed for vaccine manufacturing. In a May 2020

Reuters interview, a Pfizer executive indicated that the company planned to rely on its "network of around 200 outside contractors, which includes Catalent Inc, Lonza Group AG, and Thermo Fisher Scientific Inc, to play a bigger role in producing some of its existing medicines." 75 There were also the examples from Catalent and IDT Biologika suddenly breaking arrangements with other pharmaceutical companies in order to use their plants to fill and finish COVID-19 vaccines.

There were other, potentially large, resource allocation inefficiencies that may have also resulted in capacity underutilization. Novavax, which had reserved a number of vaccine manufacturing facilities, experienced delays in getting its vaccine through clinical trials. CureVac similarly lined up capacity at a number of plants before its disappointing Phase 3 trials were revealed in June 2021. Did these efforts tie up production that could have been used to make more of one of the other vaccines authorized for use? These experiences highlight an important trade-off-reserving capacity for one vaccine ends up taking away capacity that could have been used to manufacture another vaccine, at least over some set period of time. In response to some of these concerns, in July 2021, two policy developments emerged. First, CEPI and partners in COVAX launched a "marketplace" intended to match vaccine manufacturers in need of critical inputs with available supplies. The new mechanism would allow for the potential reallocation of inputs made idle by vaccine candidates that failed to gain regulatory approval. The idea was for CEPI to work confidentially to "identify matching offers and requests and connect potential matches, prioritising based on objective criteria including whether the manufacturer has a COVAX advance purchase agreement and WHO emergency use listing in place" (CEPI 2021).

Second, the WTO published a joint indicative list of critical inputs for COVID-19 vaccines, after convening an expert technical symposium on vaccine supply chains (WTO 2021). Trade facilitation could help eliminate bottlenecks at the border caused by product misclassifications or regulatory misunderstandings that might slow production.

Learning by doing-or the process of becoming more productive, the more output generated-was supposedly critical for new vaccine manufacturing. Examples include the slow increase in production at Other examples were more subtle. Even ultimate success stories, like Pfizer, admitted the need to scale back 2020 production targets in November because "some early batches of the raw materials failed to meet the standards." 77 In January 2021, it made the equivalent statement for its European targets: "As part of the normal productivity improvements to increase capacity, we must make modifications to the process and facility that will require additional regulatory approvals. [Although this will] temporarily impact shipments in late January to early February, it will provide a significant increase in doses available for patients in late February and March." 78 Pfizer's learning-by-doing is captured in a February interview with USA Today, in which Pfizer indicated that it had cut the amount of time to make a batch of its COVID-19 vaccine nearly in half-from 110 to 60 days, indicating, "just in the last month we've doubled output." 79 Output also increased through other means. In January, the EMA announced that six-not five-doses could be extracted from a single Pfizer vial, increasing supplies by 20 percent. 80 In February 2021, Pfizer/BioNTech learned that the vaccine was stable under less rigorous conditions and thus did not need ultra-cold storage. 81 The FDA later granted approval to weaken the conditions, implying fewer unused doses would have to be destroyed due to thawing and harder-to-access destinations could be more easily reached. e. How did the modular, fragmented structure of the industry affect scaling up?

CDMOs ended up playing a critical role in numerous vaccine supply chains. Had the vaccines instead been produced only by large, integrated pharmaceutical companies, the outcomes would probably have been different.

Having to mix and match various smaller firms along the supply chain required more coordination and transactions costs-i.e., starting new relationships at arm's length-which were made more difficult by the pandemic, which severely curtailed travel. Relative to an integrated firm, the fragmented structure may also have made technology transfer harder, learning-by-doing slower, and lessons learned more difficult to share.

However, fragmentation may also have had considerable benefits. One was transparency. Arm's length contractual arrangements (and press statements) yielded more information to the public and to policymakers about the progress of vaccine production. Fragmentation may also have increased competition and made it easier to reallocate resources and production capacity toward the most promising vaccine candidates. Finally, to fill and finish 500 million doses, it may have been easier to find capacity at five different contract manufacturers each able to produce 100 million doses than to a find one integrated company able to both manufacture the drug substance and fill and finish 500 million doses in house.

Headlines throughout the vaccine rollout in early 2021 highlighted hoarding, vaccine nationalism, and implicit and explicit export restrictions. The failure to distribute vaccines based on global public health needs under the COVAX program was a failure of first-order importance. The explicit (and entrenched) America First approach of the Trump administration even before the pandemic made clear that the rest of the world could not rely on American exports for vaccines. That explicit stance, as well as the implicit fear that other countries would do the same thing, almost certainly contributed to many company decisions to establish parallel supply chains in different markets rather than building out additional capacity in the United States or any other single location.

Yet, there is also evidence that international interdependence played a positive role. Exports were the only way many countries would receive any vaccines at all. Given that the pandemic showed lockdowns could affect industrial production (albeit in other sectors), simply scaling up mega-facilities in fewer countries and further reducing geographic diversification may not have resulted in more output.

Furthermore, some of the arguments about export restrictions on inputs may turn out to have been overblown. (Only data will resolve the issue.) Exports of key inputs may not have been much larger even without the use of DPA. Put differently, inputs were in short supply globally, and most of the firms willing to pay for those inputs were located in the United States or other high-income countries where manufacturing was taking place. A bigger policy failure than export restrictions on raw materials and equipment may have been the insufficient public investment to scale up of global production of those critical inputs in the first place. 

This article is protected by copyright. All rights reserved

In the eight months following authorization of the first COVID-19 vaccine for emergency use, the impact of the vaccines on public health and economic activity was positive but still emerging. By the end of July 2021, 

This article is protected by copyright. All rights reserved 

Supply-Chain Obstacles Led to Last Month's Cut to Pfizer's Covid-19 Vaccine-Rollout Target

Pfizer to Temporarily Reduce Covid Vaccine Deliveries to Europe

Pfizer Expects to Cut Covid-19 Vaccine Production Time by Close to 50% as Production Ramps Up, Efficiencies Increase

A controversy then arose over who would get access to those doses, as the contracts were for doses, not vials. The European Commission initially thought it had more doses than expected, but Pfizer cut back its delivery of vials, expanding supplies elsewhere

BioNTech/Pfizer Covid Vaccine No Longer Needs Ultra-Cold Storage

Covid-19 Vaccine Manufacturing in US Races Ahead

Moderna Gets Permission to Fill Covid-19 Vaccine Vials with More Doses

De-Globalisation? Global Value Chains in the Post-COVID-19 Age

The Tragedy of Vaccine Nationalism: Only Cooperation Can End the Pandemic

Vaccine Nationalism Will Prolong the Pandemic. A Global Problem Calls for Collective Action

The Real Vaccine Procurement Problem: Why America Should Make Its Supply Chain More Transparent', Foreign Affairs

How the United States Marched the Semiconductor Industry into Its Trade War with China

Forthcoming), How COVID-19 Medical Supply Shortages Led to Extraordinary Trade and Industrial Policy

Here's How to Get Billions of COVID-19 Vaccine Doses to the World ', PIIE Trade and Investment Policy Watch

The US Did Not Ban Exports Of Vaccine Supplies. But More Help Is Needed

This article is protected by copyright. All rights reserved